PD-1 blockade induces responses by inhibiting adaptive immune resistance

Paul C. Tumeh(University of California, Los Angeles), Christina L. Harview(University of California, Los Angeles), Jennifer H. Yearley(Merck & Co., Inc., Rahway, NJ, USA (United States)), I. Peter Shintaku(University of California, Los Angeles), Emma Taylor(University of California, Los Angeles), Lídia Robert(University of California, Los Angeles), Bartosz Chmielowski(University of California, Los Angeles), Marko Spasić(University of California, Los Angeles), Gina Henry(University of California, Los Angeles), Voicu Ciobanu(University of California, Los Angeles), Alisha N. West(University of California, Los Angeles), Manuel Carmona(University of California, Los Angeles), Christine Kivork(University of California, Los Angeles), Elizabeth Seja(University of California, Los Angeles), Grace Cherry(University of California, Los Angeles), Antonio Gutiérrez(University of California, Los Angeles), Tristan Grogan(University of California, Los Angeles), Christine Mateus(Institut Gustave Roussy), Gorana Tomasic(Inserm), John A. Glaspy(UCLA Jonsson Comprehensive Cancer Center), Ryan Emerson(Adaptive Biotechnologies (United States)), Harlan Robins(Adaptive Biotechnologies (United States)), Robert H. Pierce(Merck & Co., Inc., Rahway, NJ, USA (United States)), David Elashoff(UCLA Jonsson Comprehensive Cancer Center), Caroline Robert(Institut Gustave Roussy), Antoni Ribas(UCLA Jonsson Comprehensive Cancer Center)

Nature

November 25, 2014

Cited by 6,606Open Access